vs
CALAVO GROWERS INC（CVGW）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是CALAVO GROWERS INC的1.7倍（$207.3M vs $124.7M），CALAVO GROWERS INC净利率更高（3.1% vs -62.0%，领先65.1%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -26.6%），CALAVO GROWERS INC自由现金流更多（$1.2M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -1.2%）
卡拉沃种植者公司是一家国际化农产消费品企业，核心业务涉及牛油果及其他鲜果、新鲜预制食品的包装与分销，产品面向全球各地的餐饮门店、零售卖场以及个人客户供应，是生鲜果蔬领域颇具规模的供应商。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CVGW vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $124.7M | $207.3M |
| 净利润 | $3.8M | $-128.6M |
| 毛利率 | 9.3% | — |
| 营业利润率 | -1.4% | -54.7% |
| 净利率 | 3.1% | -62.0% |
| 营收同比 | -26.6% | 25.9% |
| 净利润同比 | 2846.0% | 3.5% |
| 每股收益（稀释后） | $0.22 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $124.7M | $207.3M | ||
| Q3 25 | $178.8M | $159.9M | ||
| Q2 25 | $190.5M | $166.5M | ||
| Q1 25 | $154.4M | $139.3M | ||
| Q4 24 | $170.0M | $164.6M | ||
| Q3 24 | $179.6M | $139.5M | ||
| Q2 24 | $184.4M | $147.0M | ||
| Q1 24 | $127.6M | $108.8M |
| Q4 25 | $3.8M | $-128.6M | ||
| Q3 25 | $4.7M | $-180.4M | ||
| Q2 25 | $6.8M | $-115.0M | ||
| Q1 25 | $4.4M | $-151.1M | ||
| Q4 24 | $-139.0K | $-133.2M | ||
| Q3 24 | $-732.0K | $-133.5M | ||
| Q2 24 | $6.1M | $-131.6M | ||
| Q1 24 | $-6.3M | $-170.7M |
| Q4 25 | 9.3% | — | ||
| Q3 25 | 10.2% | — | ||
| Q2 25 | 9.5% | — | ||
| Q1 25 | 10.2% | — | ||
| Q4 24 | 9.7% | — | ||
| Q3 24 | 11.2% | — | ||
| Q2 24 | 11.1% | — | ||
| Q1 24 | 8.4% | — |
| Q4 25 | -1.4% | -54.7% | ||
| Q3 25 | 4.8% | -106.9% | ||
| Q2 25 | 4.0% | -64.8% | ||
| Q1 25 | 3.3% | -102.6% | ||
| Q4 24 | 1.8% | -74.3% | ||
| Q3 24 | 5.2% | -94.6% | ||
| Q2 24 | 4.0% | -79.1% | ||
| Q1 24 | -2.4% | -151.9% |
| Q4 25 | 3.1% | -62.0% | ||
| Q3 25 | 2.6% | -112.8% | ||
| Q2 25 | 3.6% | -69.0% | ||
| Q1 25 | 2.9% | -108.5% | ||
| Q4 24 | -0.1% | -80.9% | ||
| Q3 24 | -0.4% | -95.7% | ||
| Q2 24 | 3.3% | -89.5% | ||
| Q1 24 | -4.9% | -156.8% |
| Q4 25 | $0.22 | $-1.28 | ||
| Q3 25 | $0.26 | $-1.81 | ||
| Q2 25 | $0.38 | $-1.17 | ||
| Q1 25 | $0.25 | $-1.57 | ||
| Q4 24 | $-0.01 | $-1.34 | ||
| Q3 24 | $-0.04 | $-1.40 | ||
| Q2 24 | $0.34 | $-1.52 | ||
| Q1 24 | $-0.35 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $61.2M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $206.9M | $-80.0M |
| 总资产 | $292.2M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $61.2M | $421.0M | ||
| Q3 25 | $63.8M | $202.5M | ||
| Q2 25 | $60.4M | $176.3M | ||
| Q1 25 | $48.5M | $127.1M | ||
| Q4 24 | $57.0M | $174.0M | ||
| Q3 24 | $1.1M | $150.6M | ||
| Q2 24 | $4.3M | $480.7M | ||
| Q1 24 | $5.7M | $112.3M |
| Q4 25 | $206.9M | $-80.0M | ||
| Q3 25 | $206.4M | $9.2M | ||
| Q2 25 | $206.6M | $151.3M | ||
| Q1 25 | $202.9M | $144.2M | ||
| Q4 24 | $200.3M | $255.0M | ||
| Q3 24 | $205.2M | $346.8M | ||
| Q2 24 | $207.3M | $432.4M | ||
| Q1 24 | $202.5M | $140.3M |
| Q4 25 | $292.2M | $1.5B | ||
| Q3 25 | $301.2M | $1.2B | ||
| Q2 25 | $321.5M | $1.3B | ||
| Q1 25 | $298.9M | $1.3B | ||
| Q4 24 | $301.1M | $1.5B | ||
| Q3 24 | $382.4M | $1.5B | ||
| Q2 24 | $411.4M | $1.6B | ||
| Q1 24 | $394.7M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $1.2M | $-100.8M |
| 自由现金流率自由现金流/营收 | 1.0% | -48.6% |
| 资本支出强度资本支出/营收 | 0.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.60× | — |
| 过去12个月自由现金流最近4个季度 | $19.4M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $2.3M | $-99.8M | ||
| Q3 25 | $8.0M | $-91.4M | ||
| Q2 25 | $15.7M | $-108.3M | ||
| Q1 25 | $-4.4M | $-166.5M | ||
| Q4 24 | $10.8M | $-79.3M | ||
| Q3 24 | $11.4M | $-67.0M | ||
| Q2 24 | $2.1M | $-77.0M | ||
| Q1 24 | $58.0K | $-190.7M |
| Q4 25 | $1.2M | $-100.8M | ||
| Q3 25 | $7.3M | $-92.7M | ||
| Q2 25 | $15.6M | $-110.7M | ||
| Q1 25 | $-4.7M | $-167.8M | ||
| Q4 24 | $10.5M | $-79.5M | ||
| Q3 24 | $11.3M | $-68.6M | ||
| Q2 24 | $745.0K | $-79.0M | ||
| Q1 24 | $-972.0K | $-193.9M |
| Q4 25 | 1.0% | -48.6% | ||
| Q3 25 | 4.1% | -58.0% | ||
| Q2 25 | 8.2% | -66.5% | ||
| Q1 25 | -3.1% | -120.5% | ||
| Q4 24 | 6.2% | -48.3% | ||
| Q3 24 | 6.3% | -49.2% | ||
| Q2 24 | 0.4% | -53.7% | ||
| Q1 24 | -0.8% | -178.2% |
| Q4 25 | 0.9% | 0.5% | ||
| Q3 25 | 0.4% | 0.8% | ||
| Q2 25 | 0.1% | 1.5% | ||
| Q1 25 | 0.2% | 1.0% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.1% | 1.2% | ||
| Q2 24 | 0.7% | 1.4% | ||
| Q1 24 | 0.8% | 3.0% |
| Q4 25 | 0.60× | — | ||
| Q3 25 | 1.69× | — | ||
| Q2 25 | 2.29× | — | ||
| Q1 25 | -1.00× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CVGW
| Fresh Products | $104.7M | 84% |
| Segment Prepared | $14.5M | 12% |
| Tomatoes | $4.6M | 4% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
